RS53562B1 - Tripeptidi, inhibitori hepatitisa c - Google Patents
Tripeptidi, inhibitori hepatitisa cInfo
- Publication number
- RS53562B1 RS53562B1 YU20090459A YUP9401A RS53562B1 RS 53562 B1 RS53562 B1 RS 53562B1 YU 20090459 A YU20090459 A YU 20090459A YU P9401 A YUP9401 A YU P9401A RS 53562 B1 RS53562 B1 RS 53562B1
- Authority
- RS
- Serbia
- Prior art keywords
- mmol
- mixture
- amino
- alkyl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Postupak odvajanja enantiomerae smeše metil estra 1-amino-2-vinilciklopropil karboksilne kiseline, ili njegove N-zaštićene smeše, obuhvata korake tretiranja navedene smeše sa esterazom kako bi se dobio željeni enantiomer metil estra 1 -amino-2-vinilciklopropiI karboksilne kiseline ili njegov N-zaštitni oblik.Prijava sadrži još 7 patentih zahteva.
Description
OBLASTPRONALASKA
Ovaj se pronalazak odnosi na postupak odvajanja enentiomerne smeše derivata 1-aminociklopropil karboksilne kiseline kao što je definisano u zahtevima.
Jimenez at al opisuje u Tetrahedron Pismima 35/32: 5945-5948 (1994), sterokontrolisani sintetički put do enantiočistoće derivata 1-aminociklopropan-l-Karboksilne kiseline.
Fliche at al opisuje u Svnthetic Communications 24 (20): 2873-2876 (1994), sintezu (1R,2S) i (1S,2S) dehidrokoronaminskih kiselina sukcesivno korišćenjem dve esteraze sa različitim regioselektivitetima i konvencionalnom hernijom.
Yee et al opisuje u J Org. Chem 57: 3525-3527 (1992) postupak za enzimsko odvajanje estara a-supstituisane karboksilne kiseline.
Spero i Kapadia opisuju u J Org Chem 61: 7398-7401 (1996), enentioselektivnu sintezu derivata a,a-disusptituisane amino kiseline preko enzimskog odvajanja.
Sledeći tripeptidi su inhibitori NS3 proteaze hepatitis C virusa.
u kojoj B jeste H, C-6 ili Cioaril, C7.16aralkil; Het ili (niži aIkil)-Het, svaka od njih eventualno supstituisana sa Ci_6alkilom; C1-6alkoksi; C1-6alkanoil; hidroksi; hidroksialkil; halogeno; halogenoalkil; nitro; cijano;, cijanoalkil; amino grupa eventualno supstituisana sa Ci? alkilom; amido; ili (niži alkil)amid; ili, B jeste acil derivat formule R4-C(0)-; karboksil formule Rt-O-C(O)-; amid formule R4-N(R5)-C(0)-; tioamid formule R4-N(R5)-C(S)-; ili sulfonil formule RrSOigde R4 jeste grupa, (i) Ci.10alkil opciono supstituisana sa grupom karboksil, Ci_6alkanoil, hidroksi, C1.6alkoksi, amino grupom opciono mono- ili di-supstituisanom sa grupom C1.6alkil, amido ili (niži alkil)amid; (ii) C3.7cikloalkil, C3.7cikloalkoksi, ili C4.10alkilcikloalkil, sve opciono supstituisane sa grupom hidroksi, karboksil, (C1-6alkoksi)karbonil, amino opciono mono- ili di-supstituisanom sa grupom C]_6alkil, amido, ili (niži alkil)amid; (iii) amino opciono mono- ili di-supstituisana sa C1-6alkilom; amido; ili (niži alkil)amid; (iv) C6ili Cioaril ili C7_i6aralkil, sve opciono supstituisane sa grupom C1.6alkil, hidroksi, amido, (niži alkil)amid, ili amino grupa opciono mono- ili di-supstituisana sa Ci_6alkilom; ili (v) Het ili (niži alkil)-Het, obe opciono supstituisane sa grupom C1.6alkil, hidroksi, amido, (niži alkil)amid, ili amino grupa opciono mono- ili di-supstituisana sa Ci-6alkilom;
RsjeH ili Ct.6 alkil;
uz uslov, da kada R4 jeste amid ili tioamid, R4nije (ii) cikloalkoksi grupa; a Y jeste H ili C1-6alkil grupa;
R<3>jeste grupa Ci-s alkil, C3-7cikloalkil, ili C4.10alkilcikloalkil, sve eventualno supstituisane sa grupom hidroksi, Ci_6alkoksi, Ci-6tioalkil, amido, (niži alkil)amido, C6ili Cioaril, ili C7-16aralkil;
R2jeste CH2-R20, NH -R20, O -R20ili S -R20, gde R2ojeste zasićena ili nezasićena C3.7cikloalkil ili C4.10(alkilcikloalkil) grupa, od kojih su sve opciono mono-, di- ili tri-supstituisane sa R21,
ili, R20jeste C6ili Cio aril ili C7.14aralkil grupa, sve opciono mono-, di- ili tri-supstituisane sa R21,
ili, R20 jeste Het ili (niži alkil)-Het, obe opciono mono-, di- ili tri- supstituisane sa R2i,
gde svaka R21jeste nezavisno, grupa C1-6alkil; C]_6alkoksi; niži tioalkil; sulfonil;
N02; OH; SH; halogeno; halogenoalkil; amino grupa eventualno mono- ili di-supstituisana sa grupom Ci-6alkil, Cćili Cioaril, C7.14aralkil, Het ili (niži alkil)-Het;
amido grupa eventualno mono-supstituisana sa grupom C)_6alkil,C(,ili Cioaril, C7-14aralkil, Het ili (niži alkil)-Het;
karboksil; karboksi(niži alkil);Ceili Cioaril, C7-14aralkil ili Het, a pomenute aril, aralkil ili Het grupe su opciono supstituisane sa R22;
gde R22 jeste grupa C]_6alkil; C3.7cikloalkil; Ci_6alkoksi; amino opciono mono- ili di-supstituisana sa Ci_6alkilom; sulfonil; (niži alkil)sulfonil; N02;
OH; SH; halogeno; halogenoalkil; karboksil; amid; (niži alkil)amid; ili Het eventualno supstituisan sa Ci-6alkilom,
R<1>jeste H, grupa Ci-6alkil, C3-7cikloalkil, C2-6alkenil, ili C2_6alkinil, sve eventualno supstituisane sa halogenom;
ili njihova farmaceutski prihvatljiva so ili estar.
Definicije
Kako su ovde upotrebljene, sledeće definicije, ukoliko nije drugo rečeno, označavaju: Oznaka "Pl, P2 i P3", kako je ovde upotrebljena, odnosi se na položaj ostataka amino kiseline polazeći od kraja završnog C atoma peptidnih analoga pa pružajući se ka završnom N atomu [tj. Pl odnosi se na položaj 1 od završnog C atoma, P2: drugi položaj od završnog C atoma, itd.) (vidi Berger A & Schechter 1., Transactions of the Royal Societv London series(1970), B257. 249 - 264].
Skraćenice za oc-amino kiseline korišćene u ovoj prijavi prikazane su u tabeli A.
Izraz "halogeno", kako je ovde korišćen označava halogeni supstituent odabran između bromo, hloro, fluoro ili jodo naziva.
Izraz "Ci-6alkil" ili "(niži)alkiP', kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim supstituentom, označava aciklične alkil supstituente, sa pravim ili razgranatim nizom koji sadrže od 1 do šest atoma, a obuhvataju na primer, metil, etil, propil, butil,terc.-butil, heksil,1-metiletil, 1-metilpropil, 2-metilpropil, 1,1-dimetiletil.
Izraz "C3.7cikloalkil" , kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim supstituentima, označava cikloalkil supstituent koji sadrži od tri do sedam atoma ugljenika, a uključuje ciklopropil, ciklobutil, ciklopentil, cikloheksil i cikloheptil grupe.
Ovaj izraz takođe obuhvata "spiro"-cikličnu grupu, kao spiro-ciklopropil ili spiro-ciklobutil:
Izraz "nezasićeni cikloalkil" obuhvata, na primer, cikloheksenil:
Izraz "C4.10(alkilcikloalkil)", kako je ovde korišćen, označava cikloalkil radikal koji sadrži od tri do sedam atoma ugljenika, povezanih u alkil radikal, a vezani radikali sadrže do deset atoma ugljenika: na primer, ciklopropilmetil, ciklopentiletil, cikloheksilmetil, cikloheksiletil ili cikloheptiletil.
Izraz "C2-10alkenil", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označava alkil radikal kao što je gore definisano, koji sadrži od 2 do 10 atoma ugljenika, a sadrži još i bar jednu duplu vezu. Na primer, alkenil uključuje alil i vinil.
Izraz "C|.6alkanoil", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označava prave ili razgranate 1-oksoalkil radikale koji sadrže jedan do šest atoma ugljenika i obuhvata formil, acetil, 1-oksopropil (propionil), 2-metil-l-oksopropil, 1-oksoheksil i slično.
Izraz "Ci.6alkoksi", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označava radikal -0(Ci_6alkil), gde alkil kao što je gore definisano sadrži do 6 atoma ugljenika. Alkoksi obuhvata metoksi, etoksi, propoksi, 1-metiletoksi, butoksi i 1,1-dimetiletoksi. Poslednji radikal je obično poznat kao/erc.-butoksi.
Izraz "C3.7cikloalkoksi", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označava C3.7cikloalkil grupu vezanu za atom kiseonika, kao što je na primer:
Izraz "Cćili Cioaril", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označava ili aromatsku monocikličnu grupu koja sadrži 6 atoma ugljenika ili aromatsku bicikličnu grupu koja sadrži 10 atoma ugljenika. Na primer, aril uključuje fenil, 1-naftil ili 2-naftil.
Izraz "C7-16aralkil ", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označavaCeili Cioaril, kao što je gore definisano, vezan za alkil grupu, gde alkil definisan kao gore sadrži od 1 do 6 atoma ugljenika. C7.16aralkil obuhvata na primer, benzil, butilfenil i 1-naftilmetil.
Izraz "amino aralkil", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označava amino grupu supstituisanu sa C7.16aralkil grupom, kao na primer, amino aralkil:
Izraz "(niži alkil)amid", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označava amid, mono-supstituisan sa C|.6alkilom, kao što je:
Izraz "karboksi(niži)alkil", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označava karboksil grupu (COOH) vezanu preko (niži)alkil grupe, kao što je gore definisano a obuhvata na primer buternu kiselinu.
Izraz "heterocikl" ili "Het", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugim radikalom, označava monovalentan radikal dobijen uklanjanjem vodonika iz peto-, {esto- ili sedmo-članog zasićenog ili nezasićenog (uključujući aromat) heterocikla koji sadrži od jedan do četiri hetero-atoma odabranih od azota, kiseonika i sumpora. Dalje, "Het", kako je ovde korišćeno, označava heterociklično jedinjenje kao što je definisano gore, "stopljeno" u jedan ili vi{e drugih prstenova, bili oni hetero-prstenovi ili drugi prstenovi. Primeri pogodnih heterocikla obuhvataju: pirolidin, tetrahidrofuran, tiazolidin, pirol, tiofen, diazepin, lH-imidazol, izoksazol, tiazol, tetrazol, piperidin, 1,4-dioksan, 4-morfolin, piridin, pirimidin, tiazolo[4,5-b]piridin, hinolin ili indol, ili slede}e heterocikle:
Izraz "(niži alkil)-Het", kako je ovde korišćen, označava heterocikličan radikal kao što je gore definisano vezan preko prave ili razgranate alkil grupe, pri čemu alkil, definisan kao gore, sadrži do 1 do 6 atoma ugljenika. Primeri (niži alkil)-Het obuhvataju:
Izraz "farmaceutski prihvatljiv estar", kako je ovde korišćen, bilo sam ili u kombinaciji sa drugi supstituentom, označava estre jedinjenja formule I, u kojoj su karboksilne funkcije molekula, a prvenstveno karboksi zavšetak. zamenjeni alkoksikarbonil funkcijom:
u kojoj je deo R, estra, odabran od alkila (npr. metil, etil,n-propil,/-butil,«-butil); alkoksialkila (npr. metoksimetil); alkoksiacila (npr. acetoksimetil); aralkila (npr. benzil; ariloksialkila (npr. fenoksimetil); arila (npr. fenil), eventualno supstituisan sa halogenom, Cmalkil ili Ci? alkoksi grupom. Drugi pogodni prolek estri mogu se naći u Design ofprodrugs, Bundgaard, H. Ed. Elsevier (1985), uključenim ovim kao referenca. Takvi farmaceutski ptihvatljivi estri obično hidrolizujuin vivokada se injektuju u sisara i transformišu se u oblik kiseline jedinjenja formule I.
Sto se tiče gore opisanih estara, ukoliko nije drukčije specificirano, svaki prisutan alkil deo prvenstveno sadrži 1 do 16 atoma ugljenika, naročito 1 do 6 atoma ugljenika. Svaki aril deo u takvim estrima prvenstveno sadrži fenil grupu.
Naročito, estri mogu biti Ci_i6alkil estar, neki nesupstituisani benzil estar ili benzil estar supstituisan sa bar jednom halogenom, C1.6alkil, C,^alkoksi, nitro ili trifiuormetil grupom.
Izraz "farmaceutski prihvatljiva so", kako je ovde korišćen, obuhvata one izvedene od farmaceutski prihvatljivih baza. Primeri pogodnih baza obuhvataju holin, etanolamin i etilendiamin. Na<+>, K<+>i Ca++ soli takođe dolaze u obzir kao predmet pronalaska (vidi takođe Pharmaceutical salts, Birge, S.M. et al., J. Pharm. Sci., (1977), 66, 1 -19).
Pl je ciklopropil prsten u kome ugljenik 1 imaRkonfiguraciju,
a R1 je etil, vinil, ciklopropil, 1 ili 2-bromoetil ili 1 ili 2-bromovinil.
Jedinjenja prema ovom pronalasku sintetizuju se prema opštem postupku kao što je prikazano na shemi I (gde CPG jeste karboksilna zaštitna grupa a APG je amino zaštitna grupa):
Sinteza 4 moguća izomera 2- supstituisane t- aminociklopropil- karboksilne kiseline
Sinteza je izvedena prema shemi VI.
a) Ukratko, đi-protektovan malonat Via i 1,2-dihalogenoalkan VIb ili ciklični sulfat Vic (sintetizovano prema K. Burgess i Chun-Yen KE (Svnthesis, (1996), 1463 - 1467),
reagovali su pod baznim uslovima dajući diestar Vid.
b) Regioselektivnom hidrolizom manje zaklonjenog estra dobijena je kiselina Vle.
c) Ta kiselina Vic je podvrgnuta pregrupisavanju po Curtius-u dajući racemsku smešu
derivata l-aminociklopropil-karboksilne kiseline Vlf sa R<1>usynpoložaju u odnosu na
karboksilnu grupu. Specifičan način izvođenja te sinteze prikazanje u primeru 9.
d, e) Alternativno, selektivno stvaranje estra od kiselline Vle, sa pogodnim halogenidom (P CI) ili alkoholom (P OH), daje diestar VIg u kome je P estar kompatibilan sa selektivnom hidrolizom P estra. Hidroliza P estra daje kiselinu VIh.
f) PregrupisavanjeVIh,po Curtius-u, daje racemsku smešu derivata 1-aminociklopropil-karboksilne kiseline Vli sa R<l>grupom uantipoložaju u odnosu na
karboksilnu grupu. Specifičan način izvođenja te sinteze prikazanje u primeru 14.
Alternativna sinteza za pripremanje derivata Vllf (kada R<1>jeste vinil, a nalazi se usynpoložaju prema karboksil grupi) opisana je u narednom tekstu.
Tretman komercijalno dostupnih, ili koji se lako mogu pripremiti, imina Vila sa 1,4-dihalogenobutenomVllbu prisustvu baze, posle hidrolize dobijenog imina VIIc, dajeVlldsa alil supstituentom usynpoložaju u odnosu na karboksilnu grupu. Specifični načini izvođenja tog postupka prikazani su u primeru 15 i 19.
Razdvajanje svih gornjih enantiomernih smeša ugljenika 1 (Vle i Vlld) može da se izvede putem:
enzimskog razdvajanja (primeri 13, 17 i 20) sa esterazom.
Sledeće odvajanje, utvrđivanje apsolutne stereohemije se može izvesti kao što je prikazano u Primeru 11.
Enantiomersko odvajanje i stereohemijsko određivanje se može izvesti na isti način kao i za enantiomerske smeše na ugljeniku 1 gde je supstituent na C2antiu odnosu na karboksilnu grupu (VII).
PRIMERI
Primeri koji se ne odnose na postupak koji je definisan u zahtevima su samo za svrhu reference.
Ovaj pronalazak je ilustrovan podrobnije sledećim primerima kojima se pronalazak ne ograničava.
Temperature su date u stepenima po Celzijusu. Procentni rastvori daju odnos mase prema zapremini, a odnosi rastvora izra'avaju odnos zapremine prema zapremini, ukoliko nije drukčije dato. Spektri nuklearne magnetne rezonance (NMR) snimani su na spektrometru Bruker 400 MHz; hemijska pomeranja (8) data su u delovima na 1 milion. Fleš hromatografija je rađena na silikagelu (Si02) prema postupku Still fleš hromatografske tehnike (W.C. Still at al., J. Org. Chem., (1978), 43 2923).
Skraćenice upotrebljene u primerima obuhvataju: Bn: benzil; Boe:lerc-butiloksi-karbonil {Me3COC(0)}; BSA: goveđi serumski albumin; CHAPS: 3-[(3-holamido-propil)-dimetilamonio]-l-propansulfonat; DBU: l,8-diazabiciklo[5.4.0]undek-7-en; CH2CI2= DCM: metilenhlorid; DEAD: dietilazodikarboksilat; DIAD: diizopropil-azodikarboksilat; DIEA: diizopropiletilamin; DIPEA: dizipropiletilamin; DMAP: dimetilaminopiridin; DCC: 1,3-dicikloheksilkarbodiimid; DME: 1,2-dimetiloksietan; DMF: dimetilformamid; DMSO: dimetilsulfoksid; DTT: ditiotreitol ili treo-1,4--dimerkapto-2,3-butandiol; DPPA: difenilfosforil azid; EDTA: etilendiamin-tetrasirćetna kiselina; Et: etil; EtOH: etanol; EtOAc: etilacetat; Et20: dietiletar; HATU: [0-7-azabenzotriazol-l-il)-l,l,3,3-tetrametiluronijum heksafluorofosfat]; HPLC: tečna hromatografija pod visokim pritiskom; MS: masena spektrometrija (MALD1-TOF: Matrix Assisted Laser Disorption Ionization-Time od Flight, FAB: bombardovanje brzim atomima); LAH: litijum-aluminjum-hidrid; Me: metil; MeOH: metanol; MES: (2-{N-morfolino}etan-sulfonska kiselina); NaHMDS: natrijum bis(trimetilsilil)-amid; NMM: N-metilmorfolin; NMP: N-metilpirolidin; Pr: propil: Suce: 3-karboksipropanoil; PNA: 4-nitrofenilamino ili p-nitroanilid; TBAF: tetra-n--butilamonijum-fluorid; TBTU: 2(lH-benzotriazol-l-il)-l,l,3,3-tetrametiluronijum tetrafluoroborat; TCEP: tris(2-karboksietil)fosfin hidrohlorid; TFA: trifluoro-sirćetna kiselina; THF: tetrahidrofuran; TIS: triizopropilsilan; TLC: tankoslojna hromatografija; TMSE: trimetilsililetil; Tris/HCl: tris(hidroksimetil)aminometan hidrohlorid.
PRIMER 9
A) Sinteza sme{e( 1R, 2R)/( 1S, 2R)1 -amino-2-etilcikIopropiI-karboksiIne kiseline
a) U suspenziju benziltrietilaminijum-hlorida (21,0 g, 92,19 mmol) u 50% vodenom rastvoru NaOH (92,4 g u 185 ml H2O), jedno za drugim, dodati sud\- terc-butil-malonat (20,0 g, 92,47 mmol) i 1,2-dibrombutan (30,0 g, 138,93 mmol). Reakciona smeša je snažno mešana rokom noći na sobnoj temperaturi, pa je dodata smeša leda i vode. Sirovi proizvod je ekstrahovan sa CH2CI2(3x), pa jedno za drugim, opran je vodom (3x) i rastvorom soli. Organski sloj je osušen (MgS04), profiitriran pa koncentrovan. Ostatak je prečišćen fleš hromatografljom (7 cm, 2 do 4% Et20 u heksanu), dajući žljeni derivat ciklopropana 9c (19,1 g, 70,7 mmol, prinos 76%). *H NMR (CDC13) 5 1,78 - 1,70 (m, IH), 1,47 (s, 9H), 1,46 (s, 9H), 1,44 - 1,39 (m, IH), 1,26 - 1,64 (m, 3H), 1,02 (t, 3H, J = 7,6 Hz). b) U suspenziju kalijum-ferc -butoksida (6,71 g, 59,79 mmol, 4,4 ekv.) u suvom etru (100 ml), na 0 °C dodata je H20 (270 jal, 15,00 mmol, 1,1 ekv.). Posle 5 min, u suspenziju je dodat diestar 9c (3,675 g, 13,59 mmol) u etru (10 ml). Reakciona smeša je tokom noći mešana na sobnoj temperaturi, zatim je izlivena u smešu leda i vode pa je oprana etrom (3x). Vodeni sloj je zakiseljen sa 10% aq. rastvorom limunske kiseline, na 0 °C pa je ekstrahovan sa AcOEt (3x). Sjedinjeni organski slojevi su, jedno za drugim, oprani vodom (2x) i vodenim rastvorom soli. Posle uobičajenog tretmana (Na2S04, filtriranje, koncentrovanje), željena kiselina 9d je izolovana kao bledožuto ulje (1,86 g, 8,68 mmol, prinos 64%).<1>H NMR (CDCI3) 8 2,09 - 2,01 (m, IH), 1,98 (dd, J = 3,8, 9,2 Hz, IH), 1,81 - 1,70 (m, IH), 1,66 (dd, J = 3,0, J = 8,2 Hz, IH), 1,63 - 1,56 (m, IH), 1,51 (s, 9H), 1,0 (t, J = 7,3 Hz, 3H). c) U kiselinu 9d (2,017 g, 9,414 mmol) u suvom benzenu (32 ml), jedno za drugim, su dodati Et3N (1,50 ml, 10,76 mmol, 1,14 ekv.) i DPPA (2,20 ml, 10,21 mmol, 1,08 ekv.).
Reakciona smeša je refluksovana 3,5 h pa je dodat 2-trimetilsililetanol (2,70 ml, 18,84 mmol, 2,0 ekv.). Refluks je održavan tokom noći, zatim je reakciona smeša razblažena sa Et20 pa je jedno za drugim, prana sa 10% vod. rastvorom limunske kiseline, vodom, zasićenim vodenim rastvorom NaHC03, vodom (2x) i vodenim rastvorom soli. Posle uobičajenog tretmana (MgS04, filtriranje, koncentrovanje) ostatak je prečišćen fleš hromatografijom (5 cm, 10% AcOEt - heksan) dajući željeni karbamat 9e (2,60 g, 7,88 mmol, prinos 84%) kao bledo'uto ulje. MS (FAB) 330 (MH<+>); 'H NMR (CDC13) 8 5,1 (bs, IH), 4,18-4,13 (m, 2H), 1,68 - 1,38 (m, 4H) 1,45 (s, 9H), 1,24 - 1,18 (m, IH), 1,00 - 0,96 (m, 5H), 0,03 (s, 9H).
d) U karbamat 9e (258 mg, 0,783 mmol) dodat je 1,0M rastvor TBAF u THF (940 u.1, 0,94 mmol, 1,2 ekv.). Posle 4,5 h dodata je dodatna količina 1,0M rastvora
TBAF (626 u.1, 0,63 mmol, 0,8 ekv.). Reakciona smeša je mešan tokom noći na sobnoj temperaturi, refluksovano je 30 min, pa je razblaženo sa AcOEt. Rastvor je, jedno za drugim, opran vodom (2x) i rastvorom soli. Posle uobičajenog tretmana (MgS04, filtriranje i koncentrovanje) izolovan je željeni amin 9f (84 mg, 0,453 mmol, prinos 58%), kao bledožuta tečnost. 'H NMR (CDC13) 8 1,96 (bs, 2H), 1,60 - 1,40 (m, 2H), 1,47 (s, 9H), 1,31 - 1,20 (m, IH), 1,14 (dd, J = 4,1, 7,3 Hz, IH), 1,02 (dd, J = 4,1, 9,2 Hz, IH), 0,94 (t, J = 7,3 Hz, 3H).
PRIMER 10
Hemijsko razdvajanjet- butil-( lR, 2R)/( 1S, 2R)l-amino-2-etilcikIopropiI-karboksilata (iz primera 9):
Jedinjenje 9e, iz primera 9 (8,50 g, 25,86 mmol) tretirano je sa IM TBAF/THF (26 ml), uz refluks 45 min. Ohla|ena reakciona smeša je razblažena sa EtOAc, oprana sa vodom (3x) i rastvorom soli (lx), zatim osušena (MgS04), profiltrirana i uparena dajući slobodni amin, kao svetložuto ulje. Slobodni amin je rastvoren u anhidrovanom CH2CI2(120 ml), pa su, jedno za drugim, dodati NMM (8,5 ml, 77,57 mmol), jedinjenje 4 (primer 4) (10,08 g, 27,15 mmol) i HATU (11,79 g, 31,03 mmol). Reakciona smeša je tokom noći mešana na sobnoj temperaturi, pa je dalja obrada izvedena kao što je prethodno opisano. Sirova dijastereomerna smeša je razdvojena pomoću fleš hromatografije (eluent - heksan : Et20; 25 : 75), dajući dipeptid10a(manje polaran eluirani deo) kao belu penu (4,42 g; 64 teor.%) i10b(polarniji eluirani deo) kao penu boje slonovače (4,5 g, 57 teor.%). U tom trenutku su oba izomera bila razdvojena ali apsolutna stereohemijska struktura još nije bila poznata.
PRIMER11
Određivanje apsolutne stereohemijske strukture jedinjenja 10a i 10b, putem korelacije sa poznatim t-butil (lR-amino-2R-etikikIopropil-karboksilatom
Prof. A. Charette, sa Univerziteta u Montrealu, dobio je jedinjenje11asa apsolutnom stereohemijskom strukturom kao što je prikazano, koja je određena pomoću rendgenske kristalografije (J. Am. Chem. Soc, 1995, 117, 12721). Jedinjenje 11a (13,2 mg, 0,046 mmol) rastvoreno je u IM HCl/EtOAc (240 u.1) pa je mešano približno 48 sati. Smeša je uparena do suva dajući jedinjenje 11b, kao svetložutu pastu, pa je ono kuplovano sa jedinjenjem 4 (18 mg, 0,049 mmol) kao što je opisano u primeru 10, upotrebom NMM (20,3 ul, 0,185 mmol) i HATU (21,1 mg, 0,056 mmol) u CH2C12. Sirovi materijal je prečišćen fleš hromatografijom (eluent - heksan : Et20; 50 : 50) dajući dipeptid 11c, kao ulje (7,7 mg; 31%). Upoređivanjem pomoću TLC, HPLC i NMR, nađeno je da je dipeptid 11c identičan sa manje polarnim jedinjenjem 10a, dobijenim u primeru 10, identifikujući tako apsolutnu stereohemijsku strukturu jedinjenja10akao( 1R, 2R).
PRIMER 12
Pripremanje( 1R, 2R)/( 1S, 2R)-l-Boc-amino-2-etilciklopropil-karboksiInekiseline (12a):
Karbamat 9e iz primera 9 (2,6 g, 7,88 mmol) mešan je 40 min u TFA, na 0 °C. Smeša je zatim koncentrovana pa razblažena sa THF (10 ml). Dodat je vodeni rastvor NaOH (700 mg, 17,5 mmol u 8,8 ml H20) pa zatim rastvor (Boc)20 (2,06 g, 9,44 mmol, 1,2 ekv.) u THF (13 ml). Reakciona smeša je mešana tokom noći na sobnoj temperaturi (pH je održavan na 8 dodavanjem 10% vodenog rastvora NaOH, kada je bilo potrebno), onda je razblaženo sa H20, oprano sa Et20 (3x) pa je na 0 °C zakiseljeno sa 10% aq. rastvorom limunske kiseline. Vodeni rastvor je ekstrahovan sa EtOAc (3x) pa je, jedno za drugim, pran sa H20 (2x) i vodenim rastvorom soli. Posle uobičajenog tretmana (MgSC»4, filtriranja i koncentrovanja), izolovana je željena amino kiselina zaštićena sa Boe (12a) (788 mg, 3,44 mmol, prinos 44%). 'H NMR (CDC13) 5 5,18 (bs, IH), 1,64 - 1,58 (m, 2H), 1,55 - 1,42 (m, 2H), 1,45 (s, 9H), 1,32 - 1,25 (m, IH), 0,99 (t, 3H, J = 7,3 Hz).
Pripremanje metilestra( 1R, 2R)/( 1S,2J?>l-Boc-amino-2-etilcikIopropil-
karboksilne kiseline (12b):
Boe derivat12a(0,30 g, 1,31 mmol) rastvoren je u Et20 (10 ml) pa je tretiran sa sveže pripremljenim diazometanom u Et20, na 0 °C, sve dok je bilo žute boje od neznatnog viška diazometana. Posle mešanja 20 min na sobnoj temperaturi, rakciona smeša je uparena do suva dajući12bkao bistro bezbojno ulje (0,32 g, 100%).<*>H NMR (CDCI3) 5 5,1 (bs, IH), 3,71 (s,3H), 1,62- 1,57 (m, 2H), 1,55 (s, 9H), 1,53 - 1,43 (m, IH), 1,28 - 1,21 (m, 2H), 0,95 (t, J = 7,3 Hz, 3H).
PRIMER 13
Enzimsko razdvajanje metil( 1R, 2R)/( 1S, 2R)Boc-l-amino-2-etiIciklopropiI-
karboksilata:
a) Enantiomerna smeša metilestra( 1S, 2R)/( 1R, 2R)l-Boc-amino-2-etilkarboksil-ne kiseline iz primera 10 (0,31 g, 1,27 mmol) rastvorena je u acetonu (3 ml) pa je onda
uz brzo mešanje razblaženo vodom (7 ml). Sa 0,05M vodenim rastvorom NaOH
podešeno je pH rastvora na 7,5 pre nego što je dodata Alcalase<®>[2,4L ekstrakt od Novo Nordisk Industrials] (300 mg). Za vreme inkubacije pH je stabilizo-vano pomoću NaOH a pH-metar je priključen da prati dodavanje rastvora NaOH. Posle 40 h smeša je razblažena sa EtOAc i H2O (sa 5 ml zas. NaHC03) pa su faze razdvojene. Vodena faza je zakiseljena sa 10% vodenim rastvorom HC1 pa je ekstrahovana sa EtOAc, osušeno je (MgS04), profiltrirano i koncentrovano, dajući kiselinu 13a (48,5 mg). Apsolutna stereohemijska struktura određena je upotrebom korelacije opisane u primerima 10 i 11.
b) Tretmanom alikvota kiseline 13a sa diazometanom u Et20, radi dobijanja metil estra, a zatim HPLC analizom uz upotrebu hiralne kolone [Chiracel<®>OD-H, 2,5%
izopropanol/heksan, izokratna], dobijenje odnos 51 : 1 (S,R) izomera.
PRIMER 14
Sinteza( 1R, 2S)/( JS, 2S)l-amino-2-etiIciklopropil-karboksilne kiseline:
Polazeći od kiseline 9d opisane u primeru 9:
c) U 9d (1,023 g, 4,77 mmol) u CH3CN (25 ml), jedno za drugim su dodati DBU (860 ul, 5,75 mmol, 1,2 ekv.) i alilbromid (620 ul, 7,16 mmol, 1,5 ekv.). Reakciona smeša je
mešana 4 h na sobnoj temperaturi pa je koncentrovana. Ostatak je razblažen sa Et20 pa je, jedno za drugim, prano sa 10% aq. rastvorom limunske kiseline (2x), H20, zasićenim vodenim rastvorom NaHC03, H20 (2x) i rastvorom soli. Posle uobičajenog tretmana (MgS04, filtracija i koncentrovanje) izolovan je željeni estar14a(1,106 g, 3,35 mmol, prinos 91%), kao bezbojno ulje. MS (FAB) 255 (MH<+>); 'H NMR (CDC13) 5 5,96 - 5,86 (m, IH), 5,37 - 5,22 (m, 2H), 4,70 - 4,65 (m, IH), 4,57 - 4,52 (m, IH), 1,87 - 1,79 (m, IH), 1,47 (s, 9H), 1,45 - 1,40 (m, IH), 1,33 - 1,24 (m, 3H), 1,03 (t, J = 7,3 Hz, 3H).
d) U estar14a(1,106 g, 4,349 mmol) u suvom CH2C12(5 ml), na sobnoj temperaturi je dodat TFA (5 ml). Reakciona smeša je mešana 1,5 h pa je koncentrovana dajući 14b
(854 mg, 4,308 mmol, prinos 99%). MS (FAB) 199 (MH<+>); 'H NMR (CDC13) 5 5,99 -
5,79 (m, IH), 5,40 - 5,30 (m, 2H), 4,71 - 4,62 (m, 2H), 2,22 - 2,00 (m, 2H), 1,95 - 1,88 (m, IH), 1,84 - 1,57 (m, 2H), 0,98 (t, J = 7,3 Hz, 3H). e) U kiselinu14b(853 mg, 4,30 mmol) u suvom benzenu (14,8 ml), jedno za drugim, dodati su Et3N (684 jul, 4,91 mmol, 1,14 ekv.) i DPPA (992 ul, 4,60 mmol, 1,07 ekv.).
Reakciona smeša je 4,5 h refluksovana pa je onda dodat 2-trimetilsililetanol (1,23 ml, 8,58 mmol, 2,0 ekv.). Refiuks je održavan tokom noći, a onda je reakciona smeša razblažena sa Et20, pa je, jedno za drugim, prana sa 10% vodenim rastvorom limunske kiseline, vodom, zasićenim vodenim rastvorom NaHC03, vodom (2x) i rastvorom soli. Posle uobičajenog tretmana (MgSC»4, filtriranje, koncentrovanje), ostatak je prečišćen fleš hromatografijom (5 cm, 10 do 15% AcOEt - heksan) dajući karbamat14c(1,212 g, 3,866 mmol, prinos 90%), kao bledožuto ulje. MS (FAB) 314 (MFT); 'H NMR (CDC13) 8 5,93 - 5,84 (m, IH), 5,32 - 5,20 (m, 2H), 5,05 (bs, IH), 4,60 - 4,56 (m, 2H), 4,20 - 4,11 (m, 2H), 1,71 - 1,60 (m, 3H), 1,39 - 1,22 (m, IH), 1,03 (t, J = 7,6 Hz, 3H), 0,96 - 0,86 (m, 1H), 0,04 (s, 9H). f) U karbamat14c(267 mg, 0,810 mmol) dodat je 1,0M rastvor TBAF u THF (1,62 ml, 1,62 mmol, 2,0 ekv.). Reakciona sme{a je me{ana tokom noći na sobnoj temperaturi, refluksovana je 30 min pa je onda razblažena sa AcOEt. Rastvor je, jedno za drugim, pran vodom (2x) i rastvorom soli. Posle uobičajenog tretmana (MgS04, filtriranje, koncentrovanje), izolovan je željeni amin14d(122 mg, 0,721 mmol, prinos 89%), kao bledožuta tečnost.<!>H NMR (CDC13) 8 5,94 - 5,86 (m, IH), 5,31 - 5,22 (m, 2H), 4,58 (d, J = 5,7 Hz, 2H), 1,75 (bs, 2H), 1,61 - 1,53 (m, 2H), 1,51 - 1,42 (m, 2H), 1,00 (t, J = 7,3 Hz, 3H), 0,70-0,62 (m, IH).
PRIMER 15
Sintezaetil-( lR, 2S)/( 1S, 2S)-l-amino-2-vinilciklopropil-karboksilata:
a) U rastvor kalijum-terc -butoksida (4,62 g, 41,17 mmol, 1,1 ekv.) u THF (180 ml), na
-78 °C je dodat komercijalno dostupni imin 15a (10,0 g, 34,41 mmol) u THF
(45 ml). Reakciona smeša je zagrejana do 0 °C pa je na toj temperaturi mešana 40 min. Smeša je onda opet rashlađena do -78 °C da bi se dodao 1,4-dibromobuten 15b (8,0 g, 37,40 mmol), mešana je 1 h na 0 °C, pa je ponovo rashlađena na -78 °C radi dodavanja kalijum-terc -butoksida (4,62 g, 41,17 mmol, 1,1 ekv.). Na kraju je
reakciona smeša mešana još jedan sat na 0 °C, pa je posle koncentrovanja dobijeno jedinjenje 15c.
b, c, d) U Et20 (265 ml) uneto je jedinjenje 15c pa je tretirano sa IM aq. rastvorom HC1 (106 ml). Posle 3,5 h na sobnoj temperaturi, slojevi su razdvojeni i vodeni sloj je opran sa Et20 (2x) pa je zaalkalisan sa zasićenim aq. rastvorom NaHC03. Željeni amin je ekstrahovan sa Et20 (3x) a sjedinjeni organski ekstrakti su oprani sa rastvorom soli. Posle uobičajenog tretmana (MgS04, filtriranje i koncentrovanje) ostatak je tretiran sa 4M rastvorom HC1 u dioksanu (187 ml, 748 mmol). Posle koncentrovanja, hidrohloridna so15dje izolovana kao braon čvrsta supstanca (2,467 g, 12,87 mmol, prinos 34%). 'H NMR (CDC13) 5 9,17 (bs, 3H), 5,75 - 5,66 (m, IH), 5,39 (d, J = 17,2 Hz, IH), 5,21 (d, J = 10,2 Hz, IH), 4,35 - 4,21 (m, 2H), 2,77 - 2,70 (m, IH), 2,05 (dd, J = 6,4,10,2 Hz, IH), 1,75 (dd, J = 6,4, 8,3 Hz IH), 1,33 (t, J = 7,0 Hz, 3H).
PRIMER 16
Pripremanjeetilestra( 1R, 2S)/( 1S, 2S)-1-Boc -amino-2-vinilciklopropil-karboksilne kiseline:
Hidrohloridna so15d(1,0 g, 5,2 mmol) i (Boc)20 (1,2 g, 5,7 mmol) ratsvoreni su u THF (30 ml) i tretirani sa DMAP (0,13 g, 1,04 mmol, 0,2 ekv.) i diizopropiletilami-nom (2,8 ml, 15,6 mmol). Reakciona smeša je mešana 24 h pre nego što je razblažena sa EtOAc (40 ml) pa je, jedno za drugim, prana sa zasićenim NaHC03(aq.), 5% vodenim rastvorom HC1 i zasićenim rastvorom soli. Organska faza je osušena (MgS04), profiltrirana i koncentrovana dajući16a(0,29 g, 23%), posle prečišćavanja fleš hromatografijom (15% EtOAc/heksan).<]>H NMR (CDC13) 5 5,80 - 5,72 (m, IH), 5,29 - 5,25 (dd, J = 17,2, 17,2 Hz, IH), 5,24 - 5,1 (bs, IH), 5,10 (dd, J = 9,2 9,2 Hz, IH), 4,22 - 4,13 (m, 2H), 2,15 - 2,04 (m, IH), 1,85 - 1,73 (bs, IH), 1,55 - 1,5 (m, IH), 1,49 (s, 9H), 1,26 (t, J = 7,3 Hz, 3H).
PRIMER 17
Enzimsko razdvajanje etil( 1R, 2S)/( 1S, 2S)l-amino-2-vinilciklopropiI-karboksilata:
a) Racemski derivat 17a (0,29 g, 1,14 mmol) rastvoren je u acetonu (5 ml) i raz-blažen sa H20 (10 ml). Sa 0,2M vodenim rastvorom NaOH podešeno je pH na 7,2 pre
nego što je dodata Alcalase<®>(300 mg). Da bi se za vreme inkubacije pH održavalo konstantnim, dodavan je rastvor NaOH pomoću titracionog ure|aja dirigovanog pH-metrom, tokom 9 dana sve dok teorijska količina baze nije bila dodata. Zatim je vršena ekstrakcija kiselinom/bazom, kao što je opisano u primeru 13, pa su izolovani nehidrolizovan estra (0,15 g, 100%) i hidrolizovan materijal (0,139 g, 95%). Analiza nehidrolizovanog estra pomoću HPLC, upotrebom hiralne kolone, utvrđen je odnos 43 : 1 željenog jedinjenja 17c, što je pripisano( R, S)stereohemijskoj strukturi, na osnovu hemijske korelacije kao što je opisano u primerima 10 i 11.
Uslovi za HPLC analizu: Chiralcel<®>OD-H (4,6 mm x 25 cm), izokratni uslovi uz upotrebu mobilne faze sa 2,5% izopropanol/heksana.
PRIMER 18
Razdvajanje( 1R, 2S)/( 1S, 2S)l-amino-2-vinilciklopropil-karboksilata putem kristalizacije sa dibenzoil-D-vinskoni kiselinom
U rastvor sirovog racemata(\ S, 2Si\ R,25) etil l-amino-2-vinilciklopropil-karboksilata [dobijen od etilestra N-(difenilmetilen)glicina (25,0 g, 93,5 mol) kao što je opisano u primeru 15] u EtOAc (800 ml) dodata je dibenzoil-D-vinska kiselina (33,5 g, 93,5 mol). Smeša je zagrevana do refluksa, ostavljena 15 min na sobnoj temperaturi a zatim ohlađena na 0 °C. Posle 30 min dobijena je bela čvrsta supstanca. Čvrsta faza je odvojena filtriranjem, oprana je sa EtOAc (100 ml) pa je osušeno na vazduhu. Čvrsta faza je suspendovana u acetonu (70 ml), sonifikovana, pa profiltrirana (3x), a zatim je dvaput prekristalisana iz vrelog acetona (deo A). Matični lugovi su koncentrovani pa je ostatak prekri stali san triput iz vrelog acetona (deo B). Oba dela amorfne čvrste supstance, soli dibenzoil-D-vinske kiseline su sjedinjena (5,53 g) i suspendovana u smeši Et20 (250 ml) i zasićenog rastvora NaHC03(150 ml). Organski sloj je opran sa rastvorom soli, osušen (MgSCU) i profiltriran. Filtrat je razblažen sa IM HCl/Et20 (100 ml) pa je koncentrovan pod smanjenim pritiskom. Uljasti ostatak je otparen sa CCU, dajući hidrohlorid etil-l-(7?>amino-2-f^-vinil-cikIopropan-karboksilata (940 mg, prinos 11%), kao belu čvrstu higroskopnu supstancu: [a]<25>D= +39,5° (c = 1,14 MeOH); [a]<25>365= +88,5° (c = 1,14 MeOH); 'H NMR (DMSO-d6) S 9,07 (bs, 2H), 5,64 (ddd, J = 17,2, 10,4, 8,7 Hz, IH), 5,36 (dd, J = 17,2, 1,6 Hz, IH), 5,19 (dd, J = 10,4, 1,6 Hz, IH), 4,24 - 4,16 (m, 2H), 2,51 - 2,45 (m, pikove ometa DMSO, IH), 1,84 (dd, J = 10,0, 6,0 Hz, IH), 1,64 (dd, J = 8,3, 6,0 Hz, IH), 1,23 (t, J = 7,1 Hz, 3H); MS (ESI) m/z 156 (MH)<+>; pomoću HPLC analize (CHIRALPAK AS<®>kolona, heks. :/'-PrOH) utvrđeno je daje enantiomerna čistoća Boe derivata 91% ee.
PRIMER 19
Pripremanje hidrohlorida metilestra( 1R, 2S)/( 1S,2£)-l-amino-2-vinilciklopropan-
- karboksilne kiseline (191)
Pripremanje imina19b
Hidrohlorid etilestra glicina 19a (1519,2 g, 10,88 mol, 1,0 ekv.) suspendovan je uterc -butilmetil etru (8 lit.). Dodati su benzaldehid (1155 g, 10,88 mol, 1 ekv.) i anhi-drovani natrijum-sulfat (773 g, 5,44 mol, 0,5 ekv.) pa je smeša ohlađena na 5 °C u kupatilu led-voda. U toku 15 min dokapan je trietilamin (2275 ml, 16,32 mol, 1,5 ekv.), (upotrebljeno 0,5 lit.terc-butilmetil etra za ispiranje) pa je smeša mešana 40 h na sobnoj temperaturi. Reakcija je prekinuta dodavanjem ledene vode (5 lit.) pa je organski sloj odvojen. Vodena faza je ekstrahovana sa terc-butilmetil etrom (1 lit.), sjedinjene organske faze su oprane smešom zasićenog rastvora NaHC03(400 ml), vode (1,6 lit.) a zatim rastvorom soli. Rastvor je osušen preko MgS04, koncentrovan pod smanjenim pritiskom a dobijeno žuto ulje je sušeno do konstantne mase, pod vakuumom. Imin19bje dobijen kao gusto žuto ulje koje očvršćava na -20 °C (2001 g, prinos 96%): 'H NMR (CDCI3, 400 MHz) 8 8,30 (s, IH), 7,79 (m, 2H), 7,48 - 7,39 (m, 3H), 4,40 (d, J = 1,3 Hz, 2H), 4,24 (q, J - 7 Hz, 2H), 1,31 (t, J = 7 Hz, 3H).
Pripremanje hidrohlorida etilestra racemske N-Boc-( 1R, 2S)/( 1S,25>l-amino-vin-ilciklopropan-karboksilne kiseline 19e: U suvom toluenu (60 ml) suspendovan je litijum-terc -butoksid (4,203 g, 52,5 mmol, 2,1 ekv.). U suvom toluenu (30 ml) rastvoreni su imin 19b (5,020 g, 26,3 mmol, 1,05 ekv.) i dibromid 19c (5,348 g, 25 mmol, 1 ekv.), pa je taj rastvor dokapa-van 30 min u rastvor LiOtBu, uz mešanje na sobnoj temperaturi. Posle završetka, tamno crvena smeša je mešana još 10 min pa je reakcija prekinuta dodavanjem vode (50 ml) iterc-butilmetil etra (TBME, 50 ml). Vodena faza je odvojena pa je po drugi put ekstrahovana sa TBME (50 ml). Organske faze su sjedinjene, dodata je IM HC1 (60 ml) pa je smeša mešana 2 h na sobnoj temperaturi. Organska faza je odvojena i ekstrahovana sa vodom (40 ml). Vodene faze su sjedinjene, zasićene solju (35 g) pa je dodat TBME (50 ml). Smeša je uz mešanje zaalkalisana do pH 13 - 14, pažjivim dodavanjem 10M NaOH. Organski sloj je odvojen a vodena faza je ekstrahovana sa TBME (2 x 50 ml). Organski ekstrakti koji su sadržavali slobodan amin19dsu sjedinjeni pa je dodatd\- terc-butildikarbonat (5,46 g, 25 mmol, 1 ekv.). Posle mešanja tokom noći na sobnoj temperaturi, TLC je pokazala nešto neproreagovalog slobodnog amina. Dodato je jošdi- terc-butildikarbonata (1,09 g, 5 mmol, 0,2 ekv.) pa je smeša refluksovana 2 h, kada je TLC analizom utvrđena potpuna konverzija19du karbamat 19e. Rastvor je ohlađen na sobnu temperaturu, osušen preko MgS04i koncentrovan pod smanjenim pritiskom. Ostatak je prečišćen fleš hromatografijom upotrebom kao eluenta 10% pa 20% EtOAc/heksana. Prečišćeni 19e je dobijen kao bistrožuto ulje koje polako očvršćava pod vakuumom (4,014 g, prinos 63%).
'H NMR (CDC13, 400 MHz) 5 5,77 (ddd, J = 17, 10, 9 Hz, 1 H), 5,28 (dd, J = 17, 1,5 Hz, IH), 5,18 (bs, IH), 5,11 (dd, J = 10, 1,5 Hz, IH), 4,24 - 4,09 (m, 2H), 2,13 (q, J = 8,5 Hz, IH), 1,79 (bm, IH); 1,46 (m, IH), 1,45 (s, 9H), 1,26 (t, J = 7 Hz, 3H).
Pripremanje jedinjenja 19f, navedenog u naslovu, putem reesterifikacije estra 19e: Etilestar 19e (10,807 g, 42,35 mmol) rastvoren je u suvom metanol (50 ml) pa je dodat rastvor natrijum-metoksida u MeOH (25% mas./mas., 9,7 ml, 42 mmol, 1 ekv.). Smeša je zagrevana 2 h na 50 °C, u kom trenutku je TLC analizom utvrđena potpuna reesterifikacija (19e Rf0,38, 19f Rf0,34, u 20% EtOAc/heksan). Reakciona smeša je ohlađena na sobnu temperaturu i zakiseljen do pH 4 korišćenjem 4M HC1 u dioksanu. Istaloženi NaCl je uklonjen filtriranjem (upotrebljenterc-butilmetil etar za ispiranje) pa su isparljivi sastojci uklonjeni pod smanjenim pritiskom. Na ostatak je dodatterc -butilmetil etar (100 ml) pa su čvrste supstance uklonjene filtriranjem. Uparavanjem filtrata pod smanjenim pritiskom i sušenjem pod vakuumom dobijen je čist metilestar19f (10,11g, prinos 99%).
'H NMR (CDCI3, 400 MHz) 6 5,75 (ddd, J = 17, 10, 9 Hz, IH), 5,28 (dd, J = 17, 1 Hz, IH), 5,18 (bs, IH), 5,11 (ddd, J = 10, 1,5, 0,5 Hz, IH), 3,71 (s, 3H), 2,14 (q, J = 9 Hz, IH), 1,79 (bm, IH), 1,50 (bm, IH), 1,46 (s, 9H).
PRIMER 20
Enzimsko razdvajanje hidrohlorida metilestra( 1R,25>-I-amino-2-vinilciklo-propan-karboksilne kiseline
Pripremanje metilestra N-Boc-(7/?, 2S)-l-amino-2-vinilpropan-karboksilne kiseline, 20a: Racemski estar19f(0,200 g, 0,83 mmol) rastvoren je u acetonu (3 ml) pa je dodata voda (7 ml). Dodat je 0,05M NaOH (1 kap) da se pH rastvora dovede na~8 pa je onda dodata Alcalase® 2,4L (Novo Nordisk Biochem, 0,3 g u 1 ml vode). Smeša je energično mešana na sobnoj temperaturi, održavanjem pH rastvora na 8, upotrebom automatskog titratora. Na početku 4. i 5. dana mešanja, pri pH 8, unet je dodatni enzimski rastvor (2 x 0,3 g). Posle ukupno 5 dana, upotrebljeno je ukupno 8,3 ml 0,05M NaOH. Reakciona smeša je razblažena sa EtOAc i vodom pa je organska faza odvojena. Posle pranja sa rastvorom soli, organski ekstrakt je osušen (MgSO-0i koncentrovan pod vakuumom. Jedinjenje 20a (0,059 g, prinos 30%) dobijeno je kao bistro ulje:<*>H NMR je identičan onom od jedinjenja 19f. HPLC (Chiralcel OD-H, 4,6 x 250 mm, izokratno 1% EtOH u heksanu, protok 0,8 ml/min): (1R, 2S)-2 Rf19,3 min (97%); (1S, 2R)-2 Rf17,0 min (3%).
Pripremanje hidrohlorida metilestra( 1R,2S>l-amino-2-vinilciklopropan-karboksilne kiseline, 20b: Jedinjenje 20a (39,96 g, 165,7 mmol) rastvoreno je u dioksanu (25 ml) pa je rastvor dokapan uz mešanje u 4M HC1 u dioksanu (Aldrich, 250 ml). Posle 45 min, TLC analiza je pokazala da je izvršeno potpuno deprotektovanje. Isparljivi sastojci su uklonjeni pod smanjenim pritiskom, a ostatak je dvaput uparavan sa MeOH (2 x 100 ml). Etar (300 ml) i MeOH (10 ml) dodati su u braon, uljasti ostatak pa je smeša mešana tokom noći na sobnoj temperaturi, dajući polučvrst precipitat. Unet je dodatni MeOH (15 ml) a mešanje je nastavljeno još 6 h, kada je žućkasta čvrsta supstanca sakupljena filtriranjem. Proizvod je opran sa 5% MeOH u etru (50 ml) i sa etrom (2 x 50 ml), osušen jein vacuo,dajući jedinjenje 20b, kao žućkastu čvrstu supstancu (22,60 g, prinos 76%). Filtrati (uklju~uju}i te~nosti od pranja), upareni su u vakuumu dajući dodatno 20b kao braon ulje (7,82 g, prinos 26%). Obe frakcije su bile dovoljno čiste za upotrebu u sintezi inhibitora proteaze HCV-a: [ct]D<25>= +38,2° (c = 1,0 MeOH).
'H NMR (400 MHz, DMSO-ds) 5 9,15 (bs, 3H), 5,65 (ddd, J = 17, 10, 9 Hz, IH), 5,36 (dd, J = 17, 1,5 Hz, IH), 5,19 (dd, J = 10, 1,5 Hz, IH), 3,74 (s, 3H), 2,50 (q, preklapa se sa signalom DMSO, J = 9 Hz, IH), 1,86 (dd, J = 10, 6 Hz, IH), 1,64 (dd, J = 8, 6 Hz,
IH).
Claims (8)
1. Postupak odvajanja enantiomerne smeše metil estra l-amino-2-vinilcikIopropil karboksilne kiseline, ili njegove N-zaštićene smeše, obuhvata korake tretiranja navedene smeše sa esterazom kako bi se dobio željeni enantiomer metil estra 1-amino-2-vinilciklopropil karboksilne kiseline ili njegov N-zaštitni oblik.
2. Postupak prema zahtevu l, gde navedena esteraza je Alcalase®.
3. Postupak odvajanja enantiomerne smeše metil( 1R, 2R)/( 1S, 2S)Boc-l-amino-2-etilciklopropil karboksilata koji ima formulu:
obuhvata tretiranje smeše sa Alcalase® kako bi se dobili proizvodi formula:
4. Postupak prema zahtevu 3 gde je smeša tretirana sa Alcalase® pod uslovima u kojima je pH kontrolisana.
5. Postupak odvajanja enantiomerne smeše etil (1R,2S)/(1S,2R) Boc-l-amino-2-vinilciklopropil karboksilata koji ima formulu:
obuhvata tretiranje smeše sa Alcalase® kako bi se dobili porizvodi formula:
6. Postupak prema zahtevu 5 gde je smeša tretirana sa Alcalase® pod uslovima u kojima je pH kontrolisana.
7. Postupak odvajanja enantiomerne smeše metil( 1R, 2S)/( 1S, 2R)Boe-1-amino-2-vinilciklopropil karboksilata koji ima formulu:
obuhvata tretiranje smeše sa Alcalase® kako bi se dobio proizvod formule:
8.Postupak prema zahtevu 7 gde je smeša tretirana sa Alcalase® pod uslovima u kojima je pH kontrolisana.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9593198P | 1998-08-10 | 1998-08-10 | |
| US13238699P | 1999-05-04 | 1999-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS53562B1 true RS53562B1 (sr) | 2015-02-27 |
Family
ID=26790767
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU20090459A RS53562B1 (sr) | 1998-08-10 | 1999-08-09 | Tripeptidi, inhibitori hepatitisa c |
| YUP-94/01A RS50798B (sr) | 1998-08-10 | 1999-08-09 | Tri-peptidi kao inhibitori hepatitisa c |
| RSP-2009/0459A RS20090459A (sr) | 1998-08-10 | 1999-08-09 | Tripeptidi, inhibitori hepatitisa c |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YUP-94/01A RS50798B (sr) | 1998-08-10 | 1999-08-09 | Tri-peptidi kao inhibitori hepatitisa c |
| RSP-2009/0459A RS20090459A (sr) | 1998-08-10 | 1999-08-09 | Tripeptidi, inhibitori hepatitisa c |
Country Status (43)
Families Citing this family (423)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100509388B1 (ko) | 1996-10-18 | 2005-08-23 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제 |
| US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| MXPA01013123A (es) * | 1999-06-25 | 2002-06-21 | Basf Ag | Genes de corynebacterium glutamicum que codifican proteinas de via metabolica. |
| AR029903A1 (es) | 2000-04-05 | 2003-07-23 | Schering Corp | Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento |
| CN101580536A (zh) | 2000-04-19 | 2009-11-18 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
| US6713502B2 (en) | 2000-05-05 | 2004-03-30 | Smithkline Beecham Corporation | Anti-infectives |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| KR20030081297A (ko) | 2000-07-21 | 2003-10-17 | 쉐링 코포레이션 | Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드 |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| DK1385870T3 (da) | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| DE60119968T2 (de) * | 2000-11-20 | 2007-01-18 | Bristol-Myers Squibb Co. | Hepatitis c tripeptid inhibitoren |
| KR20030091946A (ko) | 2000-12-12 | 2003-12-03 | 쉐링 코포레이션 | Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드 |
| SK286630B6 (sk) | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
| CA2449504A1 (en) | 2001-07-11 | 2003-01-23 | Vertex Pharmaceuticals Incorporated | Bridged bicyclic serine protease inhibitors |
| CN1289338C (zh) | 2001-09-14 | 2006-12-13 | 本田技研工业株式会社 | 用于车辆的前格栅碰撞缓冲结构 |
| US7241796B2 (en) | 2001-10-24 | 2007-07-10 | Vertex Pharmaceuticals Inc. | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| WO2003037893A1 (en) * | 2001-11-02 | 2003-05-08 | Glaxo Group Limited | Acyl dihydro pyrrole derivatives as hcv inhibitors |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US6894072B2 (en) | 2002-01-23 | 2005-05-17 | Schering Corporation | Compounds as NS3-serine protease inhibitors of hepatitis C virus |
| US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
| US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| KR20040099425A (ko) | 2002-04-11 | 2004-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 ｃ형 간염 바이러스 ｎｓ3-ｎｓ4프로테아제의 억제제 |
| JP4312711B2 (ja) * | 2002-05-20 | 2009-08-12 | ブリストル−マイヤーズ スクイブ カンパニー | ヘテロ環式スルホンアミドｃ型肝炎ウイルス阻害剤 |
| WO2004032827A2 (en) * | 2002-05-20 | 2004-04-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP4271148B2 (ja) * | 2002-05-20 | 2009-06-03 | ブリストル−マイヤーズ スクイブ カンパニー | 置換シクロアルキルｐ１’ｃ型肝炎ウイルスインヒビター |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| KR100457857B1 (ko) * | 2002-05-23 | 2004-11-18 | (주) 비엔씨바이오팜 | 2-[2-(3-인돌릴)에틸아미노]피리딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물 |
| TW200500375A (en) | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| US20040033959A1 (en) * | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| AU2003264038A1 (en) * | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
| EP1408031A1 (en) * | 2002-10-09 | 2004-04-14 | 3 D Gene Pharma | Pyrolidine derivatives useful in treatment of hepatitis C virus infection |
| DE60325498D1 (de) * | 2002-10-24 | 2009-02-05 | Glaxo Group Ltd | 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen |
| US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| CA2516016C (en) * | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| US6908901B2 (en) * | 2003-03-05 | 2005-06-21 | Boehringer Ingelheim International, Gmbh | Hepatitis C inhibitor peptide analogs |
| KR100960802B1 (ko) * | 2003-03-08 | 2010-06-01 | 주식회사유한양행 | 씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제 |
| US7148347B2 (en) * | 2003-04-10 | 2006-12-12 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
| JP4733023B2 (ja) * | 2003-04-16 | 2011-07-27 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤 |
| KR101031825B1 (ko) | 2003-04-18 | 2011-04-29 | 이난타 파마슈티칼스, 인코포레이티드 | 거대고리형 퀴녹살리닐 ｃ형 간염 세린 단백질분해효소억제제 |
| US6846836B2 (en) | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
| US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| CL2004001161A1 (es) * | 2003-05-21 | 2005-04-08 | Boehringer Ingelheim Int | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. |
| HUE029877T2 (en) | 2003-05-30 | 2017-04-28 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
| US7273851B2 (en) | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
| WO2004113365A2 (en) * | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| US20050075309A1 (en) | 2003-07-25 | 2005-04-07 | Richard Storer | Purine nucleoside analogues for treating Flaviviridae including hepatitis C |
| US7449447B2 (en) | 2003-08-26 | 2008-11-11 | Schering Corporation | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
| ES2361997T3 (es) * | 2003-09-22 | 2011-06-27 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos activos contra el virus de la hepatitis c. |
| RU2006113880A (ru) | 2003-09-26 | 2007-11-20 | Шеринг Корпорейшн (US) | Макроциклические ингибиторы сериновой протеиназы ns3 вируса гепатита с |
| WO2005037860A2 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| KR20060120166A (ko) | 2003-10-27 | 2006-11-24 | 버텍스 파마슈티칼스 인코포레이티드 | Ｈｃｖ ｎｓ３－ｎｓ４ａ 단백질분해효소 저항성 돌연변이 |
| US8187874B2 (en) | 2003-10-27 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
| EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
| US20050119318A1 (en) * | 2003-10-31 | 2005-06-02 | Hudyma Thomas W. | Inhibitors of HCV replication |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MXPA06005683A (es) * | 2003-11-20 | 2006-12-14 | Schering Corp | Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c. |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP1699558B1 (en) * | 2003-12-08 | 2009-03-11 | Boehringer Ingelheim International GmbH | Removal of ruthenium by-product by supercritical fluid processing |
| RU2006125441A (ru) | 2003-12-15 | 2008-01-27 | Джапан Тобакко Инк. (Jp) | Производные циклопропана и их фармацевтическое применение |
| GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
| ATE495185T1 (de) * | 2004-01-21 | 2011-01-15 | Boehringer Ingelheim Int | Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus |
| SE0400199D0 (sv) * | 2004-01-30 | 2004-01-30 | Medivir Ab | HCV Protease inhbitors |
| JP4902361B2 (ja) | 2004-01-30 | 2012-03-21 | メディヴィル・アクチエボラーグ | Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター |
| CN1938332B (zh) | 2004-02-04 | 2011-10-19 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| CN102911161A (zh) | 2004-02-20 | 2013-02-06 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| PT1719773E (pt) | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| DE602005021760D1 (de) | 2004-02-27 | 2010-07-22 | Schering Corp | Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
| US7186747B2 (en) | 2004-02-27 | 2007-03-06 | Schering Corporation | Compounds as inhibitors of hepatitis C virus NS3 serine protease |
| AU2005219859A1 (en) | 2004-02-27 | 2005-09-15 | Schering Corporation | Inhibitors of hepatitis C virus NS3 protease |
| EP1737821B1 (en) | 2004-02-27 | 2009-08-05 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
| US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| CN1946691A (zh) | 2004-02-27 | 2007-04-11 | 先灵公司 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的化合物 |
| US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| EP1742914A1 (en) * | 2004-02-27 | 2007-01-17 | Schering Corporation | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
| EP2399916B1 (en) * | 2004-03-12 | 2014-12-10 | Vertex Pharmaceuticals Incorporated | Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors |
| RU2006136084A (ru) * | 2004-03-15 | 2008-04-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Способ получения микроциклических соединений |
| AP2006003763A0 (en) * | 2004-03-30 | 2006-10-31 | Intermune Inc | Macrocyclic compounds as inhibitors of viral replication |
| US7754718B2 (en) | 2004-05-05 | 2010-07-13 | Yale University | Antiviral helioxanthin analogs |
| ES2328596T3 (es) | 2004-05-20 | 2009-11-16 | Schering Corporation | Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c. |
| CA2568008C (en) * | 2004-05-25 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic hcv protease inhibitors |
| CA2568379A1 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
| CA2571079A1 (en) | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| CA2556669C (en) * | 2004-06-28 | 2012-05-01 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| RS51974B (sr) * | 2004-07-16 | 2012-02-29 | Gilead Sciences Inc. | Antivirusna jedinjenja |
| UY29016A1 (es) * | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| JP4914355B2 (ja) * | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| CN101023094B (zh) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| WO2006020580A2 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
| ATE513844T1 (de) | 2004-08-27 | 2011-07-15 | Schering Corp | Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
| US8492539B2 (en) * | 2004-09-14 | 2013-07-23 | Gilead Pharmasset Llc | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| WO2006030892A1 (ja) * | 2004-09-17 | 2006-03-23 | Nippon Shinyaku Co., Ltd. | 複素環化合物の製造方法 |
| RU2007116265A (ru) | 2004-10-01 | 2008-11-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибирование протеазы ns3-ns4a вируса hcv |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7323447B2 (en) * | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2006096652A2 (en) | 2005-03-08 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
| AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2006119646A1 (en) | 2005-05-13 | 2006-11-16 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
| US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
| NZ563365A (en) * | 2005-06-02 | 2011-02-25 | Schering Corp | Combination of HCV protease inhibitors with a surfactant |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| AU2006259348B2 (en) | 2005-06-17 | 2010-07-22 | Novartis Ag | Use of sanglifehrin in HCV |
| CN101242816B (zh) * | 2005-06-30 | 2012-10-31 | 维罗贝股份有限公司 | Hcv抑制剂 |
| US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2009501732A (ja) * | 2005-07-20 | 2009-01-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| TWI387603B (zh) * | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Ｈｃｖ ｎｓ３蛋白酶抑制劑 |
| MX2008001166A (es) | 2005-07-25 | 2008-03-18 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| WO2007014922A1 (en) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| ES2373685T3 (es) | 2005-07-29 | 2012-02-07 | Tibotec Pharmaceuticals | Inhibidores macrocíclicos del virus de la hepatitis c. |
| TWI393723B (zh) | 2005-07-29 | 2013-04-21 | Tibotec Pharm Ltd | Ｃ型肝炎病毒之大環抑制劑（九） |
| CA2617099C (en) | 2005-07-29 | 2014-03-25 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| JP5230416B2 (ja) | 2005-07-29 | 2013-07-10 | テイボテク・フアーマシユーチカルズ | Ｃ型肝炎ウイルスの大員環状阻害剤 |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| CN101273042B (zh) * | 2005-07-29 | 2013-11-06 | 泰博特克药品有限公司 | 丙型肝炎病毒的大环抑制剂 |
| BRPI0614205A2 (pt) * | 2005-08-01 | 2016-11-22 | Merck & Co Inc | composto, composição farmacêutica, e, uso de composto |
| KR20080033481A (ko) * | 2005-08-02 | 2008-04-16 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제의 억제제 |
| CA2618560A1 (en) | 2005-08-09 | 2007-02-22 | Merck & Co., Inc. | Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection |
| US8076365B2 (en) | 2005-08-12 | 2011-12-13 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| PL385229A1 (pl) | 2005-08-19 | 2008-09-29 | Vertex Pharmaceuticals Incorporated | Sposoby i związki pośrednie |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| EP1934243B1 (en) | 2005-09-09 | 2011-05-25 | Boehringer Ingelheim International GmbH | Ring-closing metathesis process for the preparation of macrocyclic peptides |
| AU2006301966A1 (en) | 2005-10-11 | 2007-04-19 | Array Biopharma, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2392589A3 (en) | 2005-11-11 | 2012-06-20 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7910595B2 (en) * | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
| EP2345652A1 (en) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Antiviral compounds |
| EP1979349B1 (en) * | 2005-12-21 | 2010-07-28 | Abbott Laboratories | Anti-viral compounds |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP1991229A2 (en) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| EP1996565A2 (en) | 2006-03-08 | 2008-12-03 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole derivatives with anti-hcv activity |
| EP1993994A2 (en) | 2006-03-16 | 2008-11-26 | Vertex Pharmceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
| EP2007789B1 (en) | 2006-04-11 | 2015-05-20 | Novartis AG | Spirocyclic HCV/HIV inhibitors and their uses |
| GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| CA2651762A1 (en) | 2006-05-23 | 2007-11-29 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| US20080187516A1 (en) * | 2006-06-06 | 2008-08-07 | Ying Sun | Acyclic oximyl hepatitis c protease inhibitors |
| US7728148B2 (en) * | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
| US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
| US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
| GB0612423D0 (en) * | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| PE20080992A1 (es) * | 2006-06-26 | 2008-08-06 | Enanta Pharm Inc | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US20090035267A1 (en) * | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
| US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US7718612B2 (en) * | 2007-08-02 | 2010-05-18 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| WO2008022006A2 (en) * | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
| EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| US20090098085A1 (en) * | 2006-08-11 | 2009-04-16 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| US20080038225A1 (en) * | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
| JP2010500978A (ja) | 2006-08-17 | 2010-01-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼインヒビター |
| KR20090057035A (ko) * | 2006-08-21 | 2009-06-03 | 유나이티드 세러퓨틱스 코오포레이션 | 바이러스 감염의 치료를 위한 병용 요법 |
| US8138164B2 (en) * | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| CN101583372A (zh) * | 2006-10-24 | 2009-11-18 | 默克公司 | Hcv ns3蛋白酶抑制剂 |
| JP2010507656A (ja) * | 2006-10-24 | 2010-03-11 | メルク エンド カムパニー インコーポレーテッド | Ｈｃｖｎｓ３プロテアーゼ阻害剤 |
| AU2007318164B2 (en) * | 2006-10-27 | 2013-02-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| WO2008057209A1 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| WO2008057995A2 (en) * | 2006-11-02 | 2008-05-15 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| US7772180B2 (en) * | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5290186B2 (ja) | 2006-11-15 | 2013-09-18 | ヴァイロケム ファーマ インコーポレイテッド | フラビウイルス感染症の治療または予防用のチオフェン類似体 |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2661338C (en) | 2006-11-17 | 2015-05-12 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| CA2673111A1 (en) | 2006-12-07 | 2008-06-19 | Schering Corporation | Ph sensitive matrix formulation |
| GB0625345D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CN103224506A (zh) * | 2006-12-20 | 2013-07-31 | P.安杰莱蒂分子生物学研究所 | 抗病毒的吲哚 |
| GB0625349D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8236950B2 (en) * | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| WO2008074035A1 (en) * | 2006-12-27 | 2008-06-19 | Abbott Laboratories | Hcv protease inhibitors and uses thereof |
| US20080207528A1 (en) * | 2007-02-01 | 2008-08-28 | Syaulan Yang | Hcv protease inhibitors |
| JP2010519329A (ja) | 2007-02-27 | 2010-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ阻害剤 |
| DK2114924T3 (da) | 2007-02-27 | 2012-04-10 | Vertex Pharma | Co-krystaller og farmaceutiske sammensætninger omfattende disse |
| JP2010520200A (ja) | 2007-02-28 | 2010-06-10 | クオナトウス ファーマシューティカルズ，インコーポレイテッド | 特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法 |
| WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
| JP2010522172A (ja) * | 2007-03-23 | 2010-07-01 | シェーリング コーポレイション | Ｈｃｖｎｓ３プロテアーゼのｐ１−非エピメリ化ケトアミド阻害剤 |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
| WO2008134398A1 (en) * | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Oximyl dipeptide hepatitis c protease inhibitors |
| US8377872B2 (en) | 2007-04-26 | 2013-02-19 | Enanta Pharmaceuticals, Inc. | Cyclic P3 tripeptide hepatitis C serine protease inhibitors |
| US7910587B2 (en) * | 2007-04-26 | 2011-03-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl dipeptide hepatitis C virus inhibitors |
| US20080317712A1 (en) * | 2007-04-26 | 2008-12-25 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors |
| EP2160392A2 (en) * | 2007-05-03 | 2010-03-10 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| EP2142215B1 (en) | 2007-05-04 | 2012-03-07 | Vertex Pharmceuticals Incorporated | Combination therapy for the treatment of hcv infection |
| CN101679357A (zh) * | 2007-05-09 | 2010-03-24 | 辉瑞大药厂 | 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途 |
| WO2008141227A1 (en) * | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| GB0709791D0 (en) * | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
| WO2009005677A2 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
| EA019749B1 (ru) * | 2007-06-29 | 2014-06-30 | Джилид Сайэнс, Инк. | Противовирусные соединения |
| AU2008277440A1 (en) * | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis C infections |
| AU2008277377B2 (en) * | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| CA2693997C (en) | 2007-08-03 | 2013-01-15 | Pierre L. Beaulieu | Viral polymerase inhibitors |
| CN101835774B (zh) | 2007-08-30 | 2014-09-17 | 弗特克斯药品有限公司 | 共晶体和包含该共晶体的药物组合物 |
| GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| CN102026544A (zh) | 2007-11-14 | 2011-04-20 | 益安药业 | 大环四唑基丙型肝炎病毒丝氨酸蛋白酶抑制剂 |
| WO2009070689A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
| WO2009070692A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
| US8361958B2 (en) * | 2007-12-05 | 2013-01-29 | Enanta Pharmaceuticals, Inc. | Oximyl HCV serine protease inhibitors |
| MX2010006210A (es) * | 2007-12-05 | 2010-08-10 | Enanta Pharm Inc | Inhibidores de serina proteasa de hcv de tripeptido fluorado. |
| US8193346B2 (en) | 2007-12-06 | 2012-06-05 | Enanta Pharmaceuticals, Inc. | Process for making macrocyclic oximyl hepatitis C protease inhibitors |
| US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
| CN101903351B (zh) | 2007-12-19 | 2014-09-10 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| CA2713005A1 (en) * | 2008-01-24 | 2009-07-30 | Enanta Pharmaceuticals, Inc. | Difluorinated tripeptides as hcv serine protease inhibitors |
| MX2010008108A (es) * | 2008-01-24 | 2010-09-22 | Enanta Pharm Inc | Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo. |
| RU2490272C2 (ru) | 2008-02-04 | 2013-08-20 | Айденикс Фармасьютикалз, Инк. | Макроциклические ингибиторы серинпротеазы |
| WO2009100225A1 (en) | 2008-02-07 | 2009-08-13 | Virobay, Inc. | Inhibitors of cathepsin b |
| AU2009217551B2 (en) | 2008-02-25 | 2014-07-31 | Msd Italia S.R.L. | Therapeutic compounds |
| WO2009117594A1 (en) * | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
| TW200946541A (en) * | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| EA201071034A1 (ru) | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
| US8163921B2 (en) * | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2009241445A1 (en) * | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| WO2009134987A1 (en) * | 2008-04-30 | 2009-11-05 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors |
| US20090285774A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN101580535B (zh) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
| WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| TW201004632A (en) | 2008-07-02 | 2010-02-01 | Idenix Pharmaceuticals Inc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| PT2540350E (pt) | 2008-07-22 | 2014-08-27 | Merck Sharp & Dohme | Combinações de um composto de quinoxalina macrocílico o qual é um inibidor da protease ns3 do hcv com outros agentes do hcv |
| EP2307372B1 (en) | 2008-07-23 | 2012-04-25 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| PE20130307A1 (es) | 2008-09-16 | 2013-03-22 | Boehringer Ingelheim Int | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv |
| CA2737376A1 (en) * | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| CN102164909A (zh) | 2008-09-26 | 2011-08-24 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗hcv的吡啶或吡嗪衍生物 |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP3025727A1 (en) | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
| EP2358736A1 (en) * | 2008-10-15 | 2011-08-24 | Intermune, Inc. | Therapeutic antiviral peptides |
| KR20110074941A (ko) | 2008-10-30 | 2011-07-04 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 아릴피리돈 유도체 |
| KR20110087297A (ko) * | 2008-11-21 | 2011-08-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 경구 투여용의 강력한 ｈｃｖ 억제제의 약제학적 조성물 |
| CA2750577A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| WO2010065674A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US20100272674A1 (en) * | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102300871A (zh) * | 2008-12-19 | 2011-12-28 | 吉里德科学公司 | Hcv ns3蛋白酶抑制剂 |
| CN102256968A (zh) | 2008-12-22 | 2011-11-23 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| CA2746834A1 (en) | 2008-12-22 | 2010-07-01 | Gilead Sciences, Inc. | Antiviral compounds |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| NZ593649A (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Nucleoside analogs |
| JP2012514605A (ja) | 2009-01-07 | 2012-06-28 | サイネクシス，インコーポレーテッド | Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体 |
| WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
| GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
| US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| JP5690286B2 (ja) | 2009-03-04 | 2015-03-25 | イデニク プハルマセウティカルス，インコーポレイテッド | ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤 |
| MX2011008641A (es) | 2009-03-06 | 2011-09-06 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| EP2408449A4 (en) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS |
| SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
| WO2010118009A1 (en) * | 2009-04-06 | 2010-10-14 | Ptc Therapeutics, Inc. | Hcv inhibitor and therapeutic agent combinations |
| WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| JP2012524752A (ja) | 2009-04-25 | 2012-10-18 | エフ．ホフマン−ラ ロシュ アーゲー | 複素環式抗ウイルス化合物 |
| EP2429568B1 (en) | 2009-05-13 | 2016-08-17 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
| TWI583692B (zh) * | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| AR077004A1 (es) * | 2009-06-09 | 2011-07-27 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
| MX2011012541A (es) | 2009-06-24 | 2012-08-03 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| JP2012532146A (ja) * | 2009-07-02 | 2012-12-13 | ドクター・レディーズ・ラボラトリーズ・リミテッド | アミノビニルシクロプロパンカルボン酸誘導体の分割のための酵素および方法 |
| MY154683A (en) | 2009-07-07 | 2015-07-15 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| US8742162B2 (en) | 2009-08-10 | 2014-06-03 | Sumitomo Chemical Company, Limited | Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester |
| US8324417B2 (en) | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
| HUE030402T2 (en) * | 2009-09-15 | 2017-05-29 | Taigen Biotechnology Co Ltd | HCV protease inhibitors |
| IN2012DN02693A (sr) * | 2009-09-28 | 2015-09-04 | Intermune Inc | |
| US9193740B2 (en) * | 2009-10-19 | 2015-11-24 | Enanta Pharmaceuticals, Inc. | Bismacrocyclic compounds as hepatitis C virus inhibitors |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| EP2504329A1 (en) | 2009-11-25 | 2012-10-03 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
| MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
| MX2012007420A (es) | 2009-12-24 | 2012-07-23 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones de flavivirus. |
| US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| AU2011209051B2 (en) | 2010-01-27 | 2015-01-15 | AB Pharma Ltd. | Polyheterocyclic compounds highly potent as HCV inhibitors |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| AU2011232348A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
| EP2550268A1 (en) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| CN102869657A (zh) | 2010-03-24 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒感染的类似物 |
| TW201139438A (en) | 2010-03-24 | 2011-11-16 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| SG184324A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| EP2552203B1 (en) | 2010-04-01 | 2017-03-22 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2011149856A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
| EP2582717A2 (en) | 2010-06-15 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Hcv ns5b polymerase mutants |
| WO2012006070A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| EP2585447A2 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| WO2012006060A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| EP2606041A2 (en) | 2010-08-17 | 2013-06-26 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flaviviridae viral infections |
| JP5857053B2 (ja) | 2010-09-21 | 2016-02-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環式プロリン由来ｈｃｖセリンプロテアーゼ阻害剤 |
| CA2813093A1 (en) * | 2010-09-30 | 2012-04-05 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection |
| JP5909495B2 (ja) | 2010-10-08 | 2016-04-26 | ノバルティス アーゲー | スルファミドｎｓ３阻害剤のビタミンｅ製剤 |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| JP5906253B2 (ja) * | 2010-12-16 | 2016-04-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
| CA2822556A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| EA201390988A1 (ru) | 2010-12-30 | 2014-04-30 | Энанта Фармасьютикалз, Инк. | Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
| WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012171332A1 (zh) | 2011-06-16 | 2012-12-20 | 爱博新药研发(上海)有限公司 | 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用 |
| US20140142337A1 (en) | 2011-06-21 | 2014-05-22 | Mitsubishi Gas Chemical Company, Inc. | 1-amino-2-vinylcyclopropane carboxylic acid amide and salt thereof, and method for producing same |
| US20120328565A1 (en) | 2011-06-24 | 2012-12-27 | Brinkman John A | Antiviral compounds |
| CN102807607B (zh) * | 2011-07-22 | 2013-10-23 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用 |
| AU2012286853A1 (en) | 2011-07-26 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
| WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
| DE102012016127A1 (de) | 2011-08-31 | 2013-02-28 | Daniel Elias | Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels |
| CA2847892A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| RU2014117587A (ru) | 2011-10-10 | 2015-11-20 | Ф. Хоффманн-Ля Рош Аг | Противовирусные соединения |
| US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| DE202012012955U1 (de) | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| BR112014013649A2 (pt) | 2011-12-06 | 2020-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | métodos e agentes para o tratamento de doenças virais e usos dos referidos agentes |
| KR20140104030A (ko) | 2011-12-16 | 2014-08-27 | 에프. 호프만-라 로슈 아게 | Hcv ns5a의 억제제 |
| AU2012357940B2 (en) | 2011-12-20 | 2017-02-16 | Riboscience Llc | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
| MX350810B (es) | 2011-12-20 | 2017-09-20 | Riboscience Llc | Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc. |
| HK1204982A1 (en) | 2012-01-12 | 2015-12-11 | 勃林格殷格翰国际有限公司 | Stabilized pharmaceutical formulations of a potent hcv inhibitor |
| WO2013106344A1 (en) | 2012-01-12 | 2013-07-18 | Ligand Pharmaceuticals, Inc. | 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5' |
| US20130217644A1 (en) | 2012-02-13 | 2013-08-22 | Idenix Pharmaceuticals, Inc. | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] |
| JP6092261B2 (ja) * | 2012-02-24 | 2017-03-08 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ウイルス化合物 |
| WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| JP6165848B2 (ja) | 2012-05-22 | 2017-07-19 | イデニク ファーマシューティカルズ エルエルシー | 肝疾患のためのｄ−アミノ酸化合物 |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
| EP2906579B1 (en) | 2012-10-08 | 2018-04-18 | Idenix Pharmaceuticals LLC. | 2'-chloro nucleoside analogs for hcv infection |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| EP2909223B1 (en) | 2012-10-19 | 2017-03-22 | Idenix Pharmaceuticals LLC | Dinucleotide compounds for hcv infection |
| US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20140140951A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Rp-Nucleoside Analog |
| CN103804208B (zh) * | 2012-11-14 | 2016-06-08 | 重庆博腾制药科技股份有限公司 | 一种丙肝药物中间体的制备方法 |
| EP2938624A1 (en) | 2012-11-14 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| CN105073726B (zh) | 2013-01-23 | 2017-05-31 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒三唑衍生物 |
| WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| BR112015021429A2 (pt) | 2013-03-05 | 2017-07-18 | Hoffmann La Roche | compostos antivirais |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2014152928A2 (en) * | 2013-03-14 | 2014-09-25 | Achillion Pharmaceuticals, Inc. | Novel processes for producing sovaprevir |
| EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
| JP6366693B2 (ja) | 2013-05-16 | 2018-08-01 | リボサイエンス・エルエルシー | ４’−フルオロ−２’−メチル置換ヌクレオシド誘導体 |
| MA38678A1 (fr) | 2013-05-16 | 2017-07-31 | Riboscience Llc | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| PT3038601T (pt) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
| US20160271162A1 (en) | 2013-11-01 | 2016-09-22 | Idenix Pharmacueticals, Llc | D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv |
| EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| US9717797B2 (en) | 2013-12-05 | 2017-08-01 | International Business Machines Corporation | Polycarbonates bearing aromatic N-heterocycles for drug delivery |
| US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
| WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| US20170066795A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
| US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| AU2018335411B2 (en) | 2017-09-21 | 2024-06-27 | Riboscience Llc | 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
| KR102835299B1 (ko) | 2018-12-04 | 2025-07-18 | 브리스톨-마이어스 스큅 컴퍼니 | 다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0475255A3 (en) * | 1990-09-12 | 1993-04-14 | F. Hoffmann-La Roche Ag | Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid |
| JPH05155827A (ja) * | 1991-12-09 | 1993-06-22 | Banyu Pharmaceut Co Ltd | ｃｉｓ−２−アミノシクロプロパンカルボン酸誘導体の製造法 |
| CN1141591A (zh) * | 1994-02-23 | 1997-01-29 | 布·安格莱荻公司分子生物学研究所 | 体外再生丙型肝炎病毒(hcv)ns3蛋白酶的解蛋白活性的方法 |
| IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
| GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
| IT1277914B1 (it) * | 1995-08-22 | 1997-11-12 | Angeletti P Ist Richerche Bio | Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e |
| CA2165996C (en) * | 1995-12-22 | 2002-01-29 | Murray Douglas Bailey | Stereoselective preparation of 2-substituted succinic derivatives |
| DE19600034C2 (de) | 1996-01-02 | 2003-12-24 | Degussa | 1,1,2-Trisubstituierte Cyclopropanverbindungen, Verfahren zu deren Herstellung und Dihydroxyethyl-substituierte 1-Amino-cyclopropan-1-carbonsäure |
| US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| KR100509388B1 (ko) | 1996-10-18 | 2005-08-23 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제 |
| EP1001764A4 (en) | 1997-05-29 | 2005-08-24 | Merck & Co Inc | HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION |
| WO1999007733A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
| US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
| SE9704543D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
| US6455571B1 (en) * | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
| DE19835120C1 (de) * | 1998-08-04 | 1999-10-21 | Westfalia Separator Ag | Verfahren und Vorrichtung zum Einstellen des Flüssigkeitsgehalts des aus einer selbstentleerenden Schleudertrommel eines Separators ausgetragenen Feststoffes |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US6908901B2 (en) * | 2003-03-05 | 2005-06-21 | Boehringer Ingelheim International, Gmbh | Hepatitis C inhibitor peptide analogs |
| CA2516016C (en) * | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
-
1999
- 1999-08-05 US US09/368,866 patent/US6323180B1/en not_active Expired - Lifetime
- 1999-08-09 SI SI9931033T patent/SI1105413T1/sl unknown
- 1999-08-09 WO PCT/CA1999/000736 patent/WO2000009543A2/en not_active Ceased
- 1999-08-09 RS YU20090459A patent/RS53562B1/sr unknown
- 1999-08-09 IN IN127MUN2001 patent/IN211493B/en unknown
- 1999-08-09 IL IL14101299A patent/IL141012A0/xx unknown
- 1999-08-09 DK DK08169026.5T patent/DK2028186T3/da active
- 1999-08-09 DE DE69940817T patent/DE69940817D1/de not_active Expired - Lifetime
- 1999-08-09 SI SI9931071T patent/SI2028186T1/sl unknown
- 1999-08-09 ES ES08169026T patent/ES2405930T3/es not_active Expired - Lifetime
- 1999-08-09 ES ES99938084T patent/ES2326707T3/es not_active Expired - Lifetime
- 1999-08-09 HU HU1300080A patent/HU230701B1/hu unknown
- 1999-08-09 EE EEP200100081A patent/EE05517B1/xx unknown
- 1999-08-09 CZ CZ20090004A patent/CZ302766B6/cs not_active IP Right Cessation
- 1999-08-09 BR BRPI9917805-2B1A patent/BR9917805B1/pt active IP Right Grant
- 1999-08-09 MY MYPI99003397A patent/MY127538A/en unknown
- 1999-08-09 RS YUP-94/01A patent/RS50798B/sr unknown
- 1999-08-09 SK SK50026-2009A patent/SK288068B6/sk not_active IP Right Cessation
- 1999-08-09 PH PH11999002002A patent/PH11999002002B1/en unknown
- 1999-08-09 JP JP2000564993A patent/JP4485685B2/ja not_active Expired - Lifetime
- 1999-08-09 AT AT99938084T patent/ATE430158T1/de active
- 1999-08-09 DK DK99938084T patent/DK1105413T3/da active
- 1999-08-09 HK HK02101407.3A patent/HK1040085B/zh not_active IP Right Cessation
- 1999-08-09 EP EP08169026A patent/EP2028186B1/en not_active Expired - Lifetime
- 1999-08-09 CZ CZ20010516A patent/CZ301268B6/cs not_active IP Right Cessation
- 1999-08-09 ME MEP-2008-585A patent/ME00381B/me unknown
- 1999-08-09 TW TW088113586A patent/TWI250165B/zh not_active IP Right Cessation
- 1999-08-09 CN CNB998105503A patent/CN100339389C/zh not_active Expired - Lifetime
- 1999-08-09 RS RSP-2009/0459A patent/RS20090459A/sr unknown
- 1999-08-09 BR BRPI9913646A patent/BRPI9913646B8/pt not_active IP Right Cessation
- 1999-08-09 HU HU0105144A patent/HU229262B1/hu unknown
- 1999-08-09 PL PL346626A patent/PL204850B1/pl unknown
- 1999-08-09 ID IDW20010316A patent/ID27839A/id unknown
- 1999-08-09 TR TR2001/00432T patent/TR200100432T2/xx unknown
- 1999-08-09 CA CA2338946A patent/CA2338946C/en not_active Expired - Lifetime
- 1999-08-09 PT PT99938084T patent/PT1105413E/pt unknown
- 1999-08-09 SK SK206-2001A patent/SK286994B6/sk not_active IP Right Cessation
- 1999-08-09 KR KR1020017001786A patent/KR100631439B1/ko not_active Expired - Lifetime
- 1999-08-09 PE PE1999000800A patent/PE20000949A1/es not_active IP Right Cessation
- 1999-08-09 AU AU52731/99A patent/AU769738B2/en not_active Expired
- 1999-08-09 PT PT81690265T patent/PT2028186E/pt unknown
- 1999-08-09 NZ NZ510396A patent/NZ510396A/xx not_active IP Right Cessation
- 1999-08-09 EA EA200100228A patent/EA003906B1/ru not_active IP Right Cessation
- 1999-08-09 KR KR1020067010736A patent/KR100672229B1/ko not_active Expired - Lifetime
- 1999-08-09 EP EP99938084A patent/EP1105413B1/en not_active Expired - Lifetime
- 1999-08-09 HR HR20010102A patent/HRP20010102B1/xx not_active IP Right Cessation
- 1999-08-09 TR TR2002/00129T patent/TR200200129T2/xx unknown
- 1999-08-09 CN CN2007101407405A patent/CN101143892B/zh not_active Expired - Lifetime
- 1999-08-09 CA CA2445938A patent/CA2445938C/en not_active Expired - Lifetime
- 1999-08-10 CO CO99050714A patent/CO5261542A1/es active IP Right Grant
- 1999-08-10 AR ARP990103977A patent/AR020880A1/es active IP Right Grant
- 1999-09-08 UA UA2001031603A patent/UA75026C2/uk unknown
- 1999-09-28 SA SA99200617A patent/SA99200617B1/ar unknown
-
2000
- 2000-09-12 US US09/660,030 patent/US6268207B1/en not_active Expired - Lifetime
- 2000-09-29 US US09/675,398 patent/US6329379B1/en not_active Ceased
- 2000-11-01 US US09/703,751 patent/US6329417B1/en not_active Ceased
-
2001
- 2001-01-22 IL IL141012A patent/IL141012A/en not_active IP Right Cessation
- 2001-02-05 ZA ZA200100971A patent/ZA200100971B/en unknown
- 2001-02-07 MX MXPA06004222 patent/MX257413B/es unknown
- 2001-02-07 MX MXPA01001423 patent/MX261584B/es active IP Right Grant
- 2001-02-07 IN IN127MU2001 patent/IN2001MU00127A/en unknown
- 2001-02-08 BG BG105232A patent/BG65738B1/bg unknown
- 2001-02-09 NO NO20010683A patent/NO328952B1/no not_active IP Right Cessation
- 2001-04-06 US US09/827,976 patent/US6420380B2/en not_active Expired - Lifetime
- 2001-05-04 US US09/849,057 patent/US6410531B1/en not_active Expired - Lifetime
-
2002
- 2002-03-05 US US10/091,293 patent/US6534523B1/en not_active Ceased
-
2005
- 2005-09-30 US US11/241,899 patent/USRE40525E1/en not_active Expired - Lifetime
-
2007
- 2007-05-11 IN IN706MU2007 patent/IN2007MU00706A/en unknown
-
2008
- 2008-03-05 US US12/042,627 patent/USRE41894E1/en not_active Expired - Lifetime
- 2008-05-12 US US12/118,926 patent/USRE41356E1/en not_active Expired - Lifetime
- 2008-05-13 US US12/119,609 patent/USRE42164E1/en not_active Expired - Lifetime
- 2008-12-05 AR ARP080105301A patent/AR069583A2/es active IP Right Grant
-
2009
- 2009-01-15 IL IL196545A patent/IL196545A/en not_active IP Right Cessation
- 2009-07-23 CY CY20091100795T patent/CY1109291T1/el unknown
- 2009-11-18 JP JP2009262835A patent/JP5021711B2/ja not_active Expired - Lifetime
- 2009-11-27 AR ARP090104583A patent/AR073428A2/es not_active Application Discontinuation
-
2010
- 2010-01-05 NO NO20100004A patent/NO336663B1/no not_active IP Right Cessation
-
2013
- 2013-04-18 CY CY20131100317T patent/CY1113935T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS53562B1 (sr) | Tripeptidi, inhibitori hepatitisa c | |
| Bagley et al. | Synthesis of functionalised oxazoles and bis-oxazoles 1 | |
| EP2885276B1 (en) | Process for the preparation of pyrazole carboxylic acid derivatives | |
| ES2830266T3 (es) | Compuestos intermedios para la preparación de sacubitril y su preparación | |
| JPH0381256A (ja) | レニン阻害剤 | |
| AU2017368069B2 (en) | Process for preparation of sulfonylurea bile acid derivatives | |
| JP2021531234A (ja) | ヒトインテグリンα４β７のアンタゴニスト | |
| JPS6059226B2 (ja) | プロリン誘導体および関連化合物 | |
| EP2539334A1 (en) | Process for the preparation of -acyloxy -formamido amides | |
| US5767316A (en) | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives | |
| EP1992613A1 (en) | Process for production of 3,4-disubstituted pyrrolidine derivative and intermediate for the production | |
| AU773317B2 (en) | Pyrazinones, compositions containing such compounds | |
| RS52465B (sr) | Postupak za pripremanje visoko čistog perindoprila i intermedijera korisnih u sintezama | |
| JPWO2007142028A1 (ja) | 神経因性疼痛を抑制するピロリジン類縁体及びその製造方法 | |
| Dietz et al. | Structural verification via convergent total synthesis of dipeptide–lipids isolated from Porphyromonas gingivalis | |
| Gautier et al. | An unusual functional group interaction and its potential to reproduce steric and electrostatic features of the transition states of peptidolysis | |
| Seko et al. | Structure–activity study of l-amino acid-based N-type calcium channel blockers | |
| Di Giacomo et al. | New fast and practical method for the enantioselective synthesis of α-vinyl, α-alkyl quaternary α-amino acids | |
| Oba et al. | Synthesis of both enantiomers of cyclic methionine analogue:(R)-and (S)-3-aminotetrahydrothiophene-3-carboxylic acids | |
| Boyarskaya et al. | Synthesis of protected pseudopeptides from dicarboxylic amino acids by Mitsunobu condensation | |
| Cremonesi et al. | Stereoselective synthesis of β, ε-dihydroxy-α-amino acids by ring opening of 4, 5-dihydroisoxazolyl derivatives | |
| Katsuki et al. | The stereoselective synthesis of threo-3-hydroxy-4-amino acids. | |
| JP2000516586A (ja) | ３―ピロリン―２―カルボン酸誘導体の製法 | |
| El Rayes et al. | A convenient synthesis of new amino acid-coupled benzanilides | |
| Reyes-Rangel et al. | Enantioselective synthesis of beta-amino acids using hexahydrobenzoxazolidinones as chiral auxiliaries |